



Approved for use through 07/31/2006; OMB 0651-0031  
 U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE  
 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449a (Rev. 7-2003) <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/723,308	
			Filing Date	November 26, 2003	
			First Named Inventor	Henrik H. Jacobi	
			Art Unit	3653	
			Examiner Name	Not Yet Assigned	
Sheet	1	of	2	Attorney Docket Number	04305/100M285-US1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US-4,371,516-B1	02-01-1983	Gregory et al.	
	AB	US-5,729,958-B1	03-24-1998	Kearney et al.	
	AC	US-5,343,672-B1	09-06-1994	Kearney et al.	

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	†
		Country Code <sup>2</sup> -Number <sup>2</sup> -Kind Code <sup>2</sup> (if known)					
	BA	EP-0 346 622-A2		12-20-1989	Neo Abello SpA		
	BB	DE-107 208		07-20-1974	VEB Sächsisches Serumwerk		
	BC	DE-101 37 232-A1		02-20-2003	Dr. Pierre Foss		
	BD	WO-00/44351-A1		08-03-2000	R.P. Sherer Corporation		
	BE	WO-00/61117-A1		10-19-2000	R.P. Scherer Corporation		
	BF	EP-0 278 877-A1		08-17-1988	Medibrevex Societe Civile Dite		
	BG	EP-0 271 079-A1		06-15-1988	Immunotec Inc.		
	BH	WO-97/39698-A1		10-30-1997	Manuel Guillen		
	BI	WO-01/39800-A2		06-07-2001	The Board of Trustees of the University of Arkansas and Panacea Pharmaceuticals LLC		
	BJ	WO-99/21579-A1		05-06-1999	R.P. Sherer Corporation		
	BK	WO-02/13858-A1		02-21-2002	Smithkline Beecham Biologicals S.A.		
	BL	WO-01/56611-A1		08-09-2001	Novartis Nutrition AG		
	BM	WO-00/51593-A2		09-08-2000	West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited		
	BN	WO-91/09591-A1		07-11-1991	Mediventures Inc.		
	BO	WO-00/51568-A1		09-08-2000	Laboratories Prographarm		
	BP	WO-99/47680-A1		09-23-1999	Alk-Abello A/S		
	BQ	WO-02/40676-A2		05-23-2002	Alk-Abello A/S		
	BR	WO-03/096869-A2		11-27-2003	Alk-Abello A/S		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*\*CITE NO.: Those patent(s) or publication(s) which are marked with an double asterisk (\*\*) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	Date Considered
--------------------	-----------------

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /FC/



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449 (01/95)			<b>Complete if Known</b>		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)			Application Number	10/723,308	
			Filing Date	November 26, 2003	
			First Named Inventor	Henrik H. Jacobi	
			Art Unit	3653	
			Examiner Name	Not Yet Assigned	
Sheet	2	of	2	Attorney Docket Number	04305/100M285-US1

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
	CA	Veb Sachsches Serum, "Buccal medicament dosage forms - dissolving in the saliva and resorbed in the mouth", No. Abstract, DD-107208, XP-002257644		
	CB	J. Abecassis, et al., "Fabrication du medicament homeopathique", pages 77-99.		
	CC	Allergy Principles and Practice, Volume I, Fourth Edition, page 520.		
	CD	J. Ramirez et al., "Group 5 determination in Poideae grass pollen extracts by monoclonal antibody-based ELISA. Correlation with biologic activity", Allergy, 1997: 52, 806-813.		
	CE	Henrik Ipsen, et al., "Allergenic Extracts", Basic Science, Part I, Chapter 20, pp. 540-547.		
	CF	Dr. Lars Haugaard, et al., "A controlled dose-response study of immunotherapy with standardized, partially purified extract of house dust mite: Clinical efficacy and side effects", J. Allergy Clin Immunol, Vol. 91, No. 3, pp. 709-722.		
	CG	ELISA COMPETITION ASSAY, Quantitative determination of relative potency of allergenic extracts, pp. 15-25.		
	CH	European Pharmacopoeia, Third Edition, No. 2.5.12, page 66.		
	CI	European Pharmacopoeia, Third Edition, page 356-358.		
	CJ	The European Agency for the Evaluation of Medicinal Products, Human Medicines Evaluation Unit, Committee for Proprietary Medicinal Products (CPMP), London, March 13, 1996, pp. 1-6.		
	CK	ICH Harmonised Tropicite Guideline, "Stability Testing of New Drug Substances and Products Q1A(R2)", International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, pp. 1-15.		
	CL	Dr. Stephen R. Durham et al., "Long-Term Clinical Efficacy of Grass-Pollen Immunotherapy", The New England Journal of Medicine, August 12, 1999, pp. 468-474.		
	CM	European Pharmacopoeia, Third Edition, 1997, Pharmaceutical Technical Procedures, pp. 134-135.		
	CN	MT Lima et al., "Grass pollen sublingual immunotherapy for seasonal rhinoconjunctivitis: a randomized controlled trial", Clin. Exp. Allergy, 2002, Apr. 32(4) Abstract		
	CO	CHR HANSEN GROUP, Improving the Quality of Food and Health for People all Over the World, Annual Report September 2001, pages 27-28		
	CP	Lowenstein, H. 1980 Arb Paul Ehrlich Institute 75:122-132.		
	CQ	An International Search Report, dated March 3, 2004, which issued during the prosecution of International Application No. PCT/DK03/00784		
	CR	An International-Type Search Report dated October 24, 2004, which issued during the prosecution of Denmark Application No. DK 200300279		
	CS	An International-Type Search Report dated July 14, 2003, which issued during the prosecution of Denmark Application No. DK 200201825		

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup>Applicant's unique citation designation number (optional). <sup>3</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Frank Choi/	Date Considered	10/16/2008
--------------------	--------------	-----------------	------------

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /FC/